Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 20/20 | 0.68 |
| ▸ | BACE2 | Q9Y5Z0 | 8/20 | 0.68 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.62 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.62 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.62 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.62 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.62 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12690033 | 0.98 | BACE1 (0.69) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL12690112 | 0.89 | BACE1 (0.66) | BACE1BACE2 | |
| SCHEMBL12690222 | 0.88 | BACE1 (0.69) | BACE1BACE2PSEN1PSEN2APH1B | |
| SCHEMBL2620116 | 0.87 | BACE1 (0.76) | BACE1BACE2 | |
| SCHEMBL8035047 | 0.87 | BACE1 (0.76) | BACE1BACE2 | |
| SCHEMBL2932448 | 0.87 | BACE1 (0.76) | BACE1BACE2 | |
| SCHEMBL16966320 | 0.87 | BACE1 (0.76) | BACE1BACE2 | |
| SCHEMBL13467228 | 0.87 | BACE1 (0.65) | BACE1BACE2 | |
| SCHEMBL2620128 | 0.86 | BACE1 (0.75) | BACE1BACE2 | |
| SCHEMBL2928060 | 0.86 | BACE1 (0.75) | BACE1BACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | SHIONOGI & CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | SHIONOGI & CO., LTD. (JP) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245155-A1 | FUSED HETEROCYCLIC COMPOUND HAVING AMINO GROUP | APP, IAPP, BACE1 | BACE1 3/4885BACE2 14/4885PSEN1 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.